SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (12)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mallika, V.
Right arrow Articles by Rajappa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallika, V.
Right arrow Articles by Rajappa, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Coronary Artery Disease
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Atherosclerosis Pathophysiology and the Role of Novel Risk Factors: A Clinicobiochemical Perspective

V. Mallika

Department of Biochemistry, G.B. Pant Hospital, New Delhi, India, drvmallika{at}gmail.com

Binita Goswami

Department of Biochemistry, Maulana Azad Medical College, New Delhi, India

Medha Rajappa

Department of Ocular Biochemistry, Dr. R.P. Centre for Ophthalmic Sciences, AMS, New Delhi, India

Atherosclerosis is the root cause of the biggest killer of the 21st century. Mechanisms contributing to atherogenesis are multiple and complex. A number of theories—including the role of dyslipidemia, hypercoagulability, oxidative stress, endothelial dysfunction, and inflammation and infection by certain pathogens—have been propounded from time to time explain this complex phenomenon. Recently it has been suggested that atherosclerosis is a multifactorial, multistep disease that involves chronic inflammation at every step, from initiation to progression, and that all the risk factors contribute to pathogenesis by aggravating the underlying inflammatory process. A better understanding of the pathogenesis of atherosclerosis will aid in devising pharmaceutical and lifestyle modifications for reducing mortality resulting from coronary artery disease (CAD).

A comprehensive literature search was conducted using the Web sites of the National Library of Medicine (http:// www.ncbl.nlm.nih.gov/) and PubMed Central, the US National Library of Medicine's digital archive of life sciences literature (http:// www.pubmedcentral.nih.gov/). The data were accessed from books and journals in which relevant articles in this field were published.

The whole spectrum of coronary artery disease evolves through various events that lead to the formation and progression of atherosclerotic plaque and finally its complications. Atherosclerosis is the culprit behind coronary artery disease, cerebral vascular disease, and peripheral vascular disease. The pathogenic mechanisms are varied and complex. Of late, the role of lipoprotein (a), homocysteine, and inflammation and infection as prime culprits in pathogenesis of CAD is the subject of intense research and debate. The appreciation of the role of inflammation in atherosclerosis provides a mechanistic framework to understand the clinical benefits of newer therapeutic strategies, and a better understanding of pathogenesis aids in formulating preventive and therapeutic strategies in reducing mortality resulting from CAD.

An in-depth knowledge of the various pathogenic mechanisms involved in atherosclerosis can help in substantiating the current existing knowledge about the CAD epidemic. This knowledge will help clinicians to better manage the disease, which affects Indians in its most severe form.

References

  • Fleming RM: Angina and coronary ischemia are the result of coronary regional blood flow differences. J Amer Coll Angiol 1:127-42, 2003.
  • Schoen FJ The Heart in Robbin's Pathological Basis of Disease. 5th ed. New York: W.B. Saunders Co.; 1994:517-582.
  • Fleming RM The Pathogenesis of Vascular Disease. Textbook of Angiology. New York: Springer-Verlag; 1999:787-798.
  • Braunwald E. Heart Disease. A Textbook of Cardiovascular Disease. Vol 2, 5th ed. New York: W.B. Saunders Co.; 1997:1105-1160.
  • Alexander RW, Schlant RC, Fuster V., O'Rouke RA, Roberts R., Sonnenbuck EH Hurst's. The Heart Arteries and Veins. Vol. 1, 9th ed. New York: McGraw-Hill; 1998:1139-1196.
  • Boon NA, Fox Kaa, Bloomfield P., Bradbuny A. Cardiovascular Disease in Davidson's Principles and Practice of Medicine. 19th ed. New York: Churchill Livingstone; 2002;357-782.
  • Fauci AS, Braunwald E., Isselbacher KJ, et al. Harrison's Principles of Internal Medicine. Vol. 1, 15th ed. New York: McGraw-Hill; 2003:1377-1398.
  • Austin MA, King MC, Varnizan KM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495-506, 1990.[Abstract/Free Full Text]
  • Lamarche B., St. Pierre AC, Ruel IL A prospective population based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17:859-865, 2001.[Web of Science][Medline] [Order article via Infotrieve]
  • Blake GJ, Tvos JD, Rifai N. Low density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106:1930-1937, 2002.[Abstract/Free Full Text]
  • Lamarche B., Lemieux I., Despres JP The small dense LDL phenotype and the risk of coronary heart disease: epidemiology pathophysiology and therapeutic aspects. Diabetes Metab 25:199-211, 1999.[Web of Science][Medline] [Order article via Infotrieve]
  • Vakkilainen J., Steiner G., Ansauer JC: Relationships between low density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733-1737, 2003.[Abstract/Free Full Text]
  • Holvoet P., Mertens A., Verhamme P. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848, 2001.[Abstract/Free Full Text]
  • Hulthe J., Iagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22:1162-1167, 2002.[Abstract/Free Full Text]
  • Havel RJ Role of triglyceride rich lipoproteins in progression of atherosclerosis. Circulation 81:694-696, 1990.[Free Full Text]
  • Krauss RM Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 13B-17B, 1998.
  • Hodis HN, Mack WJ, Azen SP Triglyceride and cholesterol rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90:42-49, 1994.[Abstract/Free Full Text]
  • Alanpovic P., Mack WJ, Knight-Gibson C. The role of triglyceride rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17:715-722, 1997.[Abstract/Free Full Text]
  • Sigurdsson G., Baldursdottir A., Sigvaldason H. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 62:1251-1254, 1992.
  • Walldius G., Jungner I., Holmer I. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026-2033, 2001.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sacks FM, Alaupovic P., Moye LA: VLDL, apolipoproteins B, C III and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102:1886-1892, 2000.[Abstract/Free Full Text]
  • Schaefer EJ, McNamara JR, Shan PK: Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25:989-994, 2002.[Abstract/Free Full Text]
  • Marx N., Sukhova GK, Collins T., Libby P., Plutzky J.: PPAR {alpha} activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131, 1999.[Abstract/Free Full Text]
  • Neve BP: PPAR {alpha} agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103:207-212, 2001.[Abstract/Free Full Text]
  • Delerive P.: Peroxisome proliferator-activated receptor {alpha} negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kB and AP-I. J Biol Chem 274:32048-32054, 1999.[Abstract/Free Full Text]
  • Castro Cabezas M, Halkes CJ, Meijjssen S.: Diurnal triglyceride profiles: a novel approach to study triglyceride changes. Atherosclerosis 155:219-228, 2001.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lewis GF, O'Meara NM, Soltys PA: Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72:934-944, 1991.[Abstract/Free Full Text]
  • Patsch JR, Miesenback G., Hopferwieser T.: Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12:1336-1345, 1992.[Abstract/Free Full Text]
  • Weintraub MS, Grosskopf I., Rassin T.: Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: Case control study over three years. BMJ 312:936-939, 1996.
  • Zilversmit DB: Atherogenesis: A postprandial phenomenon. Circulation 60:473-485, 1979.[Abstract/Free Full Text]
  • Loscalzo J.: Lipoprotein (a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 10:672-679, 1990.[Free Full Text]
  • Loscalzo J., Weinfeld M., Flees GM, Scanu AM, Fogelman AM: Lipoprotein (a), fibrin binding and plasminogen activation. Arteriosclerosis 10:240-245, 1990.[Abstract/Free Full Text]
  • Lawn RM: Lipoprotein (a) in heart disease. Sci Am 266:54-60, 1992.[Web of Science][Medline] [Order article via Infotrieve]
  • Dalen GH, Guyton JR, Mohammad A.: Association of levels of lipoprotein (a), plasma lipids and other lipoproteins with coronary arteries documented by angiography. Circulation 74:758-765, 1986.[Abstract/Free Full Text]
  • Mbewu AD, Duington PN: Lipoprotein (a) structure, properties, and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 85:1-14, 1990.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Galle J., Bengen J., Schollmeyer P., Wanner C. Impairment of endothelium-dependent diation of rabbit renal arteries by oxidized lipoprotein (a). Circulation 92:1582-1589, 1995.[Abstract/Free Full Text]
  • Rosenson RS: Assessing risk across the spectrum of patients with the metabolic syndrome. Am J Cardiol 96:8E-10E, 2005.[Web of Science][Medline] [Order article via Infotrieve]
  • Sorrentino MJ: Implications of the metabolic syndrome the new epidemic. Am J Cardiol 96:3E-7E, 2005.[Web of Science][Medline] [Order article via Infotrieve]
  • Navab M.: High density lipoprotein associated enzymes: their role in vascular biology. Curr Opin Lipidol 9:449-456, 1998.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schmidt AM, Yan SD, Wautier JL, Stern D.: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Cri Res 84:489-497, 1999.
  • Miller GJ: Hemostasis and cardiovascular risk. The British and European experience. Arch Pathol Lab Med 116:1318-1321, 1992.[Web of Science][Medline] [Order article via Infotrieve]
  • Meade TW, Ruddock V., Sterling Y.: Fibrinolytic activity, clotting factors and long term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 342:1076, 1993.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Erdste E.: Plasma fibrinogen an independent cardiovascular risk factor. J Intern Med 227:365-372, 1990.[Web of Science][Medline] [Order article via Infotrieve]
  • Juhan-Vague I., Allesi MC: Plasminogen activator inhibitor and atherothrombosis. Thromb Haemost 70:138-143, 1993.[Web of Science][Medline] [Order article via Infotrieve]
  • Fleming RM Using C-reactive protein as a marker of bacterially aggravated atherosclerosis in acute coronary syndromes. J Amer Coll Angiol 2003;1:165-171, 2003.
  • Fuster V., Fayad ZA, Badimon JJ: Acute coronary syndromes: biology. Lancet 353:S115-S119, 1999.
  • Saksela O., Rifkin DB: Cell-associated plasminogen activation/regulation and physiological functions. Annu Rev Cell Biol 4:93-126, 1988.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Libby P.: Inflammation in atherosclerosis. Nature 420:868-874, 2002.[CrossRef][Medline] [Order article via Infotrieve]
  • Drexler H.: Factors involved in the maintenance of endothelial function. Am J Cardiol 82:35-45, 1998.[CrossRef]
  • Ross R.: Atherosclerosis. An inflammatory disease. N Engl J Med 340:115-126, 1999.[Free Full Text]
  • Davignon J., Ganz P.: Role of endothelial dysfunction in atherosclerosis. Circulation 109(III):III-27—III-32, 2002.
  • Harrison D., Griending KK, Landmesser U.: Role of oxidative stress in atherosclerosis. Am J Cardiol 91:7A-11A, 2003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • O'Donnell VB: Free radicals and lipid signaling in endothelial cells. Antioxid Redox Signal 5:195-203, 2003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Li D., Yang B., Mehta JL: Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, Bcl2, and Fas. Am J Physiol 275:H568-H576, 1998.[Web of Science][Medline] [Order article via Infotrieve]
  • Inoue M., Itoh H., Tanaka T. Oxidised LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator activator receptor gamma. Arterioscler Thromb Vasc Biol 21:560-566, 2001.[Abstract/Free Full Text]
  • Auge N., Garcia V., Maupas-Schwalm F.: Oxidized LDL induced smooth muscle cell proliferation involves the EGF receptor/PI-3 Kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol 22:1990-1995, 2002.[Abstract/Free Full Text]
  • Li D., Liu L., Chen H., Sawamura T., Ranganathan S., Mehta JL: Lox-I mediates OX-LDL induced expression of matrix metalloproteinase in human coronary artery endothelial cells. Circulation 107:612-617, 2003.[Abstract/Free Full Text]
  • Li D., Liu L., Chen H., Sawamura T., Mehta JL: Lox-1, an oxidized LDL endothelial receptor, induces CD40/ CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23:816-821, 2003.[Abstract/Free Full Text]
  • Libby P., Ridker PM, Maseri A.: Inflammation and atherosclerosis. Circulation 105:1135-1143, 2002.[Abstract/Free Full Text]
  • Shah PK: Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Clin 17:271-281, 1999.[CrossRef][Medline] [Order article via Infotrieve]
  • Ross R.: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809, 1993.[CrossRef][Medline] [Order article via Infotrieve]
  • Cheng Jwn, Rivera NG: Infection and atherosclerosis— focus on cytomegalovirus and chlamydia pneumoniae. Ann Pharmacother 32:1310-1316, 1998.[Abstract]
  • Mehta JL, Saldeen Tgp, Rand K.: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary disease. J Am Coll Cardiol 31:1217-1225, 1998.[Abstract/Free Full Text]
  • Kalayoglu MV, Libby P., Byrne GI: Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288:2724-2731, 2002.[Abstract/Free Full Text]
  • Fabricant CG, Fabricant J., Litrenta MM: Virus induced atherosclerosis. J Exp Med 148:335-340, 1978.[Abstract/Free Full Text]
  • Gerrity RG: The role of the monocyte in atherogenesis. Transition of blood borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181-190, 1981.[Abstract]
  • Plutzky J.: Inflammatory pathways in atherosclerosis and acute coronary syndrome. Am J Cardiol 88:10K-15K, 2001.[Web of Science][Medline] [Order article via Infotrieve]
  • Pober JS, Cotxao RS: Cytokines and endothelial cell biology. Physiol Rev 70:427-451, 1990.[Free Full Text]
  • Mehta JL, Nichols WW, Mehta P.: Neutrophils as potential participants in acute myocardial ischemia. J Am Coll Cardiol 11:1309-1316, 1988.[Abstract]
  • Hansson GK, Jonasson L., Seifert PS, Stemme S.: Immune mechanisms in atherosclerosis. Arteriosclerosis 9:567-578, 1989.[Abstract/Free Full Text]
  • Cybulsky MI, Gimbrone MA: Endothelial expression of a mononuclear leucocyte adhesion molecule during atherogenesis. Science 251:788-791, 1991.[Abstract/Free Full Text]
  • Li H., Cybulsky MI, Gimbrone MA, Libby P.: An atherogenic diet rapidly induces VCAM-1, a cytokine mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler Thromb 13:197-204, 1993.[Abstract/Free Full Text]
  • Johnson RC Absence of P-selectins delays fatty streak formation in mice. J Clin Invest 99:1037-1043, 1997.[Web of Science][Medline] [Order article via Infotrieve]
  • Dong ZM: The combined role of P-and E-selectins in atherosclerosis. J Clin Invest 102:145-152, 1998.[Web of Science][Medline] [Order article via Infotrieve]
  • Collins T., Cybulsky MI: NF-KB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107:255-264, 2001.[Web of Science][Medline] [Order article via Infotrieve]
  • Boisvert WA, Santiago R., Curtiss LK, Terkeltaub RA: A leucocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor deficient mice. J Clin Invest 101:353-363, 1998.[Web of Science][Medline] [Order article via Infotrieve]
  • Mach F.: Differential expression of three T-lymphocyte activating CXC chemokines by human atheroma associated cells. J Clin Invest 104:1041-1050, 1999.[Web of Science][Medline] [Order article via Infotrieve]
  • Haley KJ: Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway. Circulation 102:2185-2189, 2000.[Abstract/Free Full Text]
  • Rajavashisth TB: Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1 matrix metalloproteinase. J Biol Chem 274:11924-11929, 1999.[Abstract/Free Full Text]
  • Fleming RM: The effect of high, moderate and low fat diets on weight loss and cardiovascular disease risk factors. Preventive Cardiol 5:110-118, 2002.[CrossRef]
  • Fleming RM: The influence of diet on homocysteine. Fourth International Homocysteine Conference; Basel, Switzerland, June 2003.
  • Wilcken Del, Wilcken B.: The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57:1079-1082, 1976.[Web of Science][Medline] [Order article via Infotrieve]
  • Harpel PC, Chang VT, Borth W.: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin. A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89:10193-10197, 1992.[Abstract/Free Full Text]
  • Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1096-1914, 1991.
  • Nishinaga M., Ozawa T., Shimado K.: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparin sulphate expression in cultured porcine aortic endothelial cells. J Clin Invest 92:1381-1386, 1993.[Web of Science][Medline] [Order article via Infotrieve]
  • Haynes WG: Hyperhomocysteinemia. Vascular functions and atherosclerosis: effect of vitamins. Cardiovasc Drugs Ther 16:391-399, 2002.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wall R., Harlan JM, Harker LA, Striker GE: Homocysteine induced endothelial cell injury in vivo: a review. Thromb Res 18:113-121, 1980.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dudman Npb, Temple SE, Guo XW, Fu WY, Perry MA: Homocysteine enhances neutrophil endothelial interactions in vivo. Cir Res 84:409-416, 1999.[Abstract/Free Full Text]
  • Heinecke JW, Rosen H., Suzuki LA, Chait A.: The role of sulphur containing amino acids in super oxide production and modification of low density lipoprotein in arterial smooth muscle cells. J Biol Chem 262:10098-10103, 1987.[Abstract/Free Full Text]
  • Upchurch GR, Welch GN, Fabian AJ: Homocysteine decreases bioavailable Nitric Oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272:17012-17017, 1997.[Abstract/Free Full Text]
  • Hiltunen MO, via-Herttual S: DNA methylation, smooth muscle cells and atherogenesis. Arterioscler Thromb Vasc Biol 20:1557-1564, 2000.[Abstract/Free Full Text]
  • Krumkan II, Culmsee C., Chan SL, et al: Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxins. J Neurosci 20:6920-6926, 2000.[Abstract/Free Full Text]
  • Toyota Y., Yamamura T., Miyake Y., Yamamoto A.: Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis 147:77-86, 1999.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Angiology, Vol. 58, No. 5, 513-522 (2007)
DOI: 10.1177/0003319707303443
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
M. Rajappa, S.K. Sen, and A. Sharma
Role of Pro-/Anti-Inflammatory Cytokines and Their Correlation With Established Risk Factors in South Indians With Coronary Artery Disease
Angiology, August 1, 2009; 60(4): 419 - 426.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (12)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mallika, V.
Right arrow Articles by Rajappa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallika, V.
Right arrow Articles by Rajappa, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Coronary Artery Disease
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement